Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids

References

• BreivikHCollettBVentafriddaVCohenRGallacherDSurvey of chronic pain in Europe: prevalence, impact on daily life, and treatmentEur J Pain200610428733316095934
   PubMed Web of Science ®Google Scholar
• ReidKJHarkerJBalaMMEpidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impactCurr Med Res Opin201127244946221194394
   PubMed Web of Science ®Google Scholar
• SngBLSchugSAThe role of opioids in managing chronic non-cancer painAnn Acad Med Singapore2009381196096619956818
   PubMed Web of Science ®Google Scholar
• WiffenPJEvidence-based pain management and palliative care in issue one for 2005 of The Cochrane LibraryJ Pain Palliat Care Pharmacother2005193656816219616
   PubMedGoogle Scholar
• CaraceniAHanksGKaasaSEuropean Palliative Care Research Collaborative (EPCRC)European Association for Palliative Care (EAPC)Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol2012132e58e6822300860
   PubMed Web of Science ®Google Scholar
• AhmedzaiSHNauckFBar-SelaGBosseBLeyendeckerPHoppMA randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer painPalliat Med2012261506021937568
   PubMed Web of Science ®Google Scholar
• ChouRHuffmanLHAmerican Pain SocietyAmerican College of PhysiciansMedications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guidelineAnn Intern Med2007147750551417909211
   PubMed Web of Science ®Google Scholar
• KahanMMailis-GagnonAWilsonLSrivastavaANational Opioid Use Guideline GroupCanadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general populationCan Fam Physician2011571112576622084455
   PubMed Web of Science ®Google Scholar
• HäuserWBockFEngeserPTölleTWillweber-StrumpfeAPetzkeFLong-term opioid use in non-cancer painDtsch Arztebl Int20141114373274025404530
   PubMed Web of Science ®Google Scholar
• PappagalloMIncidence, prevalence, and management of opioid bowel dysfunctionAm J Surg200118211S18S11755892
   PubMed Web of Science ®Google Scholar
• ColuzziFPappagalloMNational Initiative on Pain ControlOpioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapyMinerva Anestesiol2005717–842543316012415
   PubMedGoogle Scholar
• BellTJPanchalSJMiaskowskiCBolgeSCMilanovaTWilliamsonRThe prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1)Pain Med2009101354218721170
   PubMed Web of Science ®Google Scholar
• KurzASesslerDIOpioid-induced bowel dysfunction: pathophysiology and potential new therapiesDrugs200363764967112656645
   PubMed Web of Science ®Google Scholar
• BeckerGGalandiDBlumHEPeripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic reviewJ Pain Symptom Manage200734554756517900855
   PubMed Web of Science ®Google Scholar
• PanchalSJMüller-SchwefePWurzelmannJIOpioid-induced bowel dysfunction: prevalence, pathophysiology and burdenInt J Clin Pract20076171181118717488292
   PubMed Web of Science ®Google Scholar
• OdegardPSBurkeCManagements of opioid induced constipation in elderly patientsConsultant Pharmacist1996111722
   Google Scholar
• LeppertWThe role of opioid receptor antagonists in the treatment of opioid-induced constipation: a reviewAdv Ther2010271071473020799006
   PubMed Web of Science ®Google Scholar
• MercadanteSGiarratanoACombined oral prolonged-release oxycodone and naloxone in chronic pain managementExpert Opin Investig Drugs2013221161166
   PubMed Web of Science ®Google Scholar
• MeissnerWLeyendeckerPMueller-LissnerSA randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipationEur J Pain2009131566418762438
   PubMed Web of Science ®Google Scholar
• LöwensteinOLeyendeckerPHoppMCombined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialExpert Opin Pharmacother200910453154319243306
   PubMed Web of Science ®Google Scholar
• LöwensteinOLeyendeckerPLuxEAEfficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trialsBMC Clin Pharmacol2010101220920236
   PubMedGoogle Scholar
• VondrackovaDLeyendeckerPMeissnerWAnalgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic painJ Pain20089121144115418708300
   PubMed Web of Science ®Google Scholar
• Sandner-KieslingALeyendeckerPHoppMLong-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic painInt J Clin Pract201064676377420370845
   PubMed Web of Science ®Google Scholar
• AhmedzaiSHLeppertWJaneckiMLong-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer painSupport Care Cancer201523382383025218610
   PubMed Web of Science ®Google Scholar
• BlagdenMHaferJDuerrHHoppMBosseBLong-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trialsNeurogastroenterol Motil201426121792180125346155
   PubMed Web of Science ®Google Scholar
• SchutterUGrunertSMeyerCSchmidtTNolteTInnovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practiceCurr Med Res Opin20102661377138720380506
   PubMed Web of Science ®Google Scholar
• UeberallMAMueller-SchwefeGHSafety and efficacy of oxycodone/naloxone vs oxycodone vs morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparationsCurr Med Res Opin Epub5292015
   Web of Science ®Google Scholar
• HanssonLHednerTDahlöfBProspective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-PointBlood Press1992121131191366259
   PubMedGoogle Scholar
• CryerBLiCSimonLSSinghGStillmanMJBergerMFGI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trialAm J Gastroenterol2013108339240023399552
   PubMed Web of Science ®Google Scholar
• Deutsche SchmerzgesellschaftDeutscher Schmerzfragebogen [German Pain Questionnaire]BerlinDeutsche Schmerzgesellschaft2012 Available from: http://www.dgss.org/deutscher-schmerzfragebogenAccessed April 10, 2015 German
   Google Scholar
• Deutsche SchmerzgesellschaftHandbuch zum Deutschen Schmerzfragebogen [Manual for the German Pain Questionnaire]BerlinDeutsche Schmerzgesellschaft2012 Available from: http://www.dgss.org/fileadmin/pdf/12_DSF_Manual_2012.2.pdfAccessed April 10, 2015 German
   Google Scholar
• MST Mundipharma Retardtabletten package insertMundipharma GmbHGermany2 2015 Available at: https://www.mundipharma.de/fileadmin/mundipharma-relaunch/documents/public/gebrauchsinformationen/GI_MST_10-30-60-100-200mg.pdfAccessed July 06, 2015
   Google Scholar
• Oxygesic RetardtablettenMundipharma GmbHGermany112011 Available at: https://www.mundipharma.de/fileadmin/mundipharma-relaunch/documents/public/gebrauchsinformationen/GI_Oxygesic_5-10-20-40-80mg.pdfAccessed July 06, 2015
   Google Scholar
• Targin RetardtablettenMundipharma GmbHGermany5 2014 Available at: https://www.mundipharma.de/fileadmin/mundipharma-relaunch/documents/public/gebrauchsinformationen/GI_Targin_5mg-2_5mg_10mg-5mg_20mg-10mg_40mg-20mg.pdfAccessed July 06, 2015
   Google Scholar
• Kassenärztliche Bundesvereinigung; Arzneimittelkommission der Deutschen ÄrzteschaftCurrent agents: oxycodone/naloxoneWirkstoff Aktuell: Oxycodon/NaloxonBerlinKassenärztliche Bundesvereinigung2012 German
   Google Scholar
• RentzAMYuRMüller-LissnerSLeyendeckerPValidation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipationJ Med Econ200912437138319912069
   PubMedGoogle Scholar
• UeberallMAMüller-LissnerSBuschmann-KrammCBosseBThe Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patientsJ Int Med Res2011391415021672306
   PubMed Web of Science ®Google Scholar
• Deutsche Schmerzgesellschaft: Deutscher Schmerzfragebogen [German Pain Questionnaire] Available from: http://www.dgss.org/deutscher-schmerzfragebogenAccessed July 06, 2015 German
   Google Scholar
• FrettlöhJMaierCGockelHHüppeMValidation of the German Mainz Pain Staging System in different pain syndromesSchmerz2003174240251 German12923673
   PubMed Web of Science ®Google Scholar
• Von KorffMOrmelJKeefeFJDworkinSFGrading the severity of chronic painPain19925021331491408309
   PubMed Web of Science ®Google Scholar
• LevineJDGordonNCFieldsHLNaloxone dose dependently produces analgesia and hyperalgesia in postoperative painNature19792785706740741219371
   PubMed Web of Science ®Google Scholar
• RochfordJStewartJActivation and expression of endogenous pain control mechanisms in rats given repeated nociceptive tests under the influence of naloxoneBehav Neurosci19871011871033030357
   PubMed Web of Science ®Google Scholar
• GreeleyJDLêADPoulosCXCappellH“Paradoxical” analgesia induced by naloxone and naltrexonePsychopharmacology (Berl)198896136393147475
   PubMed Web of Science ®Google Scholar
• PoulosCXKnokeDMLeADCappellHNaloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testingPsychopharmacology (Berl)1990100131352296625
   PubMed Web of Science ®Google Scholar
• WangHYFriedmanEOlmsteadMCBurnsLHUltra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signalingNeuroscience2005135124726116084657
   PubMed Web of Science ®Google Scholar
• BurnsLHWangHYUltra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approachClin Med Insights Ther20102857868
   Google Scholar
• ParolaroDSalaMGoriEEffect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxoneEur J Pharmacol1977464329338590342
   PubMed Web of Science ®Google Scholar
• StewartJJWeisbrodtNWBurksTFCentral and peripheral actions of morphine on intestinal transitJ Pharmacol Exp Ther19782053547555660528
   PubMed Web of Science ®Google Scholar
• PorrecaFCowanARaffaRBTallaridaRJKetazocines and morphine: effects on gastrointestinal transit after central and peripheral administrationLife Sci19833215178517906339861
   PubMed Web of Science ®Google Scholar
• ThörnSEWattwilMLindbergGSäweJSystemic and central effects of morphine on gastroduodenal motilityActa Anaesthesiol Scand19964021771868848916
   PubMed Web of Science ®Google Scholar
• LeppertWThe impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesContemp Oncol (Pozn)201216212513123788866
   PubMed Web of Science ®Google Scholar
• ThomasJKarverSCooneyGAMethylnaltrexone for opioid-induced constipation in advanced illnessN Engl J Med2008358222332234318509120
   PubMed Web of Science ®Google Scholar
• SlatkinNThomasJLipmanAGMethylnaltrexone for treatment of opioid- induced constipation in advanced illness patientsJ Support Oncol200971394619278178
   PubMedGoogle Scholar
• KohroTYamazakiTCardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point designHypertens Res200932210911419262468
   PubMed Web of Science ®Google Scholar